Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology (Nasdaq: OLMA) granted stock options to six new employees to purchase an aggregate 176,150 shares of common stock, effective June 1, 2026, under its 2022 Inducement Plan.

Rhea-AI Summary

Olema Oncology (Nasdaq: OLMA) granted stock options to six new employees to purchase an aggregate 176,150 shares of common stock, effective June 1, 2026, under its 2022 Inducement Plan.

Options have a 10-year term, a $12.71 exercise price, and four-year vesting, in line with Nasdaq Listing Rule 5635(c)(4).

Argus Jun 3 session

-1.68% close to close Open Argus

Details

News Market Reaction – OLMA

In the Jun 3 session, OLMA declined 1.68%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details standard inducement stock option grants for six new employees, covering 17...

Analysis

This announcement details standard inducement stock option grants for six new employees, covering 176,150 shares at an exercise price of $12.71 with a four-year vesting schedule. It follows a similar inducement grant disclosed on May 4, 2026. In the broader context, Olema recently reported larger R&D-driven losses and multiple OP-3136 clinical updates. Investors may monitor how ongoing trial milestones and capital deployment interact with continued use of equity-based compensation.

Key Figures

Inducement option shares: 176,150 shares New employees: 6 employees Vesting schedule: 4 years +5 more

Inducement option shares

176,150 shares

Aggregate options granted to six new employees effective June 1, 2026

New employees

6 employees

Recipients of inducement stock option grants

Vesting schedule

4 years

Options vest over four years subject to continued employment

Initial cliff vesting

25 percent

Vests on first anniversary of vesting commencement date

Monthly installments

36 installments

Remaining vesting in 36 equal monthly installments over three years

Option term

10 years

Contractual life of the stock options

Exercise price

$12.71 per share

Equal to last reported sale price on June 1, 2026

Reference stock price

$12.71

Nasdaq last reported sale price on June 1, 2026

Historical Context

5 past events · Latest: May 26

5 events

1. May 26

   Clinical collaboration

   24h Move

   -0.9%

   Bayer collaboration to study OP-3136 plus NUBEQA in mCRPC.

2. May 21

   Clinical data update

   24h Move

   -2.7%

   Initial Phase 1 OP-3136 data showing tolerability and anti-tumor activity.

3. May 19

   Conference participation

   24h Move

   +4.1%

   Announcement of three upcoming investor healthcare conference appearances.

4. May 12

   Earnings results

   24h Move

   -6.0%

   Larger quarterly net loss despite substantial cash and outlined milestones.

5. May 04

   Inducement grants

   24h Move

   +0.1%

   Inducement stock options for five new employees under 2022 Inducement Plan.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4)

1 terms

nasdaq listing rule 5635(c)(4) regulatory

"granted under the Company's 2022 Inducement Plan ... in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, June 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to six new employees to purchase an aggregate of 176,150 shares of the Company's common stock, effective as of June 1, 2026. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of $12.71 per share, equal to the last reported sale price of the Company's common stock as reported by Nasdaq on June 1, 2026. The stock options are subject to the terms of the Olema Pharmaceuticals, Inc., 2022 Inducement Plan.

Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.

Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock option grants did Olema Oncology (OLMA) announce on June 2, 2026?

Olema Oncology announced stock options for six new employees to purchase 176,150 common shares. According to Olema, these options were granted under its 2022 Inducement Plan as a material inducement for employment, consistent with Nasdaq Listing Rule 5635(c)(4) requirements.

What is the exercise price and term of the new Olema Oncology (OLMA) inducement options?

The new Olema Oncology inducement options have a $12.71 per share exercise price and a 10-year term. According to Olema, $12.71 equals the last reported Nasdaq sale price of its common stock on June 1, 2026, the grant’s effective date.

How do the Olema Oncology (OLMA) inducement stock options vest for new employees?

The Olema Oncology inducement options vest over four years, subject to continued employment. According to Olema, 25% vests on the first anniversary of each employee’s vesting start date, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Why did Olema Oncology (OLMA) use its 2022 Inducement Plan for these stock option grants?

Olema Oncology used its 2022 Inducement Plan to grant options as a material employment inducement. According to Olema, this approach complies with Nasdaq Listing Rule 5635(c)(4), allowing equity awards outside stockholder-approved plans for qualifying new hires.

How many Olema Oncology (OLMA) shares are covered by the June 2026 inducement option grants?

The June 2026 inducement option grants cover 176,150 shares of Olema Oncology common stock. According to Olema, these options were awarded to six new employees as part of their compensation packages to support recruiting and retention efforts.